-
公开(公告)号：US20220160702A1
公开(公告)日：2022-05-26
申请号：US17344830
申请日：2021-06-10
Applicant: The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventor： Florence Fevrier Wagner , Jennifer Q. Pan , Sivaraman Dandapani , Andrew Germain , Edward Holson , Benito Munoz , Partha P. Nag , Michael C. Lewis , Stephen J. Haggarty , Joshua A. Bishop , Kimberly Stegmaier , Michel Weiwer , Versha Banerji
IPC: A61K31/4745 , C07D471/04 , C07D471/10 , A61K31/4747
Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3β) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.
-
公开(公告)号：US20210388444A1
公开(公告)日：2021-12-16
申请号：US17325279
申请日：2021-05-20
Inventor： Thomas J. Kwiatkowski, JR. , Robert H. Brown, JR.
IPC: C12Q1/6883 , G01N33/68 , C12N15/113 , C12Q1/6837
Abstract: The invention provides novel FUS/TLS nucleic acids and proteins that comprise one or more genetic markers (for example, single nucleotide polymorphisms) and methods of use thereof including methods relating to the diagnosis of ALS or other related motor neuron disease by virtue of the presence of the mutant FUS/TLS sequence(s).
-
公开(公告)号：US20200338087A9
公开(公告)日：2020-10-29
申请号：US16389641
申请日：2019-04-19
Applicant: Dana-Farber Cancer Institute, Inc. , The Broad Institute, Inc. , President and Fellows of Harvard College , The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventor： Alykhan Shamji , Thomas Sundberg , Nathanael S. Gray , Ramnik Xavier , Stuart L. Schreiber , Hwan Geun Choi , Yanke Liang
IPC: A61K31/5377 , A61K31/519 , A61P37/00 , A61K45/06 , A61K31/506 , A61P1/00
Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate STK inhibitors of Formula (III)).
-
公开(公告)号：US20200323945A1
公开(公告)日：2020-10-15
申请号：US16841183
申请日：2020-04-06
Inventor： Ronald G. Tompkins , A. Aria Tzika , Yong-Ming Yu , Laurence Rahme , Jeevendra A. Martyn
Abstract: The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury.
-
公开(公告)号：US20190211000A1
公开(公告)日：2019-07-11
申请号：US16231324
申请日：2018-12-21
Applicant: Massachusetts Institute of Technology , The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventor： Li-Huei Tsai , Ling Pan , Stephen J. Haggarty , Debasis Patnaik
IPC: C07D405/12 , C07D307/40 , C07D411/12 , C07C217/58 , C07C219/28 , C07D409/12 , C07D307/52 , C07D487/04
CPC classification number: C07D405/12 , C07C217/58 , C07C219/28 , C07D307/40 , C07D307/52 , C07D409/12 , C07D411/12 , C07D487/04
Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).
-
Patent Agency Ranking
公开(公告)号：US20190175584A1
公开(公告)日：2019-06-13
申请号：US16198589
申请日：2018-11-21
Applicant: The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventor： Florence Fevrier Wagner , Jennifer Q. Pan , Sivaraman Dandapani , Andrew Germain , Edward Holson , Benito Munoz , Partha P. Nag , Michael C. Lewis , Stephen J. Haggarty , Joshua A. Bishop , Kimberly Stegmaier , Michel Weiwer , Versha Banerji
IPC: A61K31/4745 , C07D471/04 , A61K31/4747 , C07D471/10
Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3β) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.
-
公开(公告)号：US20180327750A1
公开(公告)日：2018-11-15
申请号：US15944330
申请日：2018-04-03
Applicant: Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventor： Kai W. Wucherpfennig , Glenn Dranoff , Penghui Zhou , Donald Shaffer , Nir Hacohen , Harvey I. Cantor , Diana Alvarez Arias
IPC: C12N15/113 , C12Q1/6886 , A61K39/00 , C07K14/725 , C07K16/32 , C12N5/0783 , A61K35/17
CPC classification number: C12N15/1137 , A61K35/17 , A61K39/0011 , A61K2039/5158 , A61K2039/585 , C07K14/7051 , C07K16/32 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/33 , C12N5/0638 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2320/31 , C12N2320/32 , C12Q1/6886 , C12Q2600/178
Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
-
公开(公告)号：US20180280551A1
公开(公告)日：2018-10-04
申请号：US15764087
申请日：2016-10-01
Applicant: Whitehead Institute for Biomedical Research , The General Hospital Corporation d/b/a Massachusetts General Hospital
Inventor： Mohammad Rashidian , Hidde L. Ploegh , Neil Vasdev , Huan Steven Liang
Abstract: Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specific ally conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.
-
公开(公告)号：US20170368108A1
公开(公告)日：2017-12-28
申请号：US15698965
申请日：2017-09-08
Applicant: Ethicon Endo-Surgery, Inc. , The General Hospital Corporation D/B/A, Massachusetts General Hospital , President and Fellows of Harvard College
Inventor： Lee M. Kaplan , Alice P. Liou , Peter J. Turnbaugh , Jason L. Harris
CPC classification number: A61K35/74 , A61K9/0053 , A61K35/741 , A61K45/06 , A61K2035/11 , C12Q1/689 , Y02A50/451 , Y02A50/473 , A61K2300/00
Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.
-
公开(公告)号：US20170217955A9
公开(公告)日：2017-08-03
申请号：US15147201
申请日：2016-05-05
Applicant: The Broad Institute, Inc. , The General Hospital Corporation d/b/a Massachusetts General Hospital , Massachusetts Institute of Technology
Inventor： Edward Holson , Florence Fevrier Wagner , Michel Weiwer , Li-Huei Tsai , Stephen J. Haggarty , Yan-Ling Zhang
IPC: C07D471/04 , A61K31/167 , C07D211/62 , A61K31/445 , C07D295/195 , A61K31/437 , C07D211/34 , C07D209/44 , A61K31/4035 , C07D209/52 , A61K31/403 , C07C237/24 , A61K31/402
CPC classification number: C07D491/107 , A61K31/167 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/397 , A61K31/402 , A61K31/403 , A61K31/4035 , A61K31/415 , A61K31/4178 , A61K31/437 , A61K31/439 , A61K31/4418 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61K31/4535 , A61K31/4545 , A61K31/496 , A61K31/4965 , A61K31/50 , A61K31/501 , A61K31/519 , A61K31/5377 , C07C211/52 , C07C233/42 , C07C233/43 , C07C233/56 , C07C233/62 , C07C235/82 , C07C237/20 , C07C237/24 , C07C271/28 , C07C275/30 , C07C275/40 , C07C281/06 , C07C2601/02 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/50 , C07D205/04 , C07D205/06 , C07D209/44 , C07D209/52 , C07D211/22 , C07D211/34 , C07D211/62 , C07D213/40 , C07D213/56 , C07D231/04 , C07D237/04 , C07D241/12 , C07D295/185 , C07D295/195 , C07D309/08 , C07D311/04 , C07D311/82 , C07D333/20 , C07D333/24 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D471/04 , C07D487/04 , C07D487/10 , C07D491/08 , C07D493/08
Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R1a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
-
-
-
-
-
-
-
-
-
Search Results
108
records
(took 0.049 seconds)
